StockNews.com Downgrades Brainstorm Cell Therapeutics (NASDAQ:BCLI) to Sell

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Brainstorm Cell Therapeutics Stock Down 6.3 %

Shares of NASDAQ BCLI opened at $2.09 on Wednesday. The stock’s 50 day moving average price is $1.74 and its two-hundred day moving average price is $3.31. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89. The stock has a market capitalization of $11.92 million, a P/E ratio of -0.44 and a beta of 0.29.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.